Loading...
•
Sep 30, 2023
Nuvation Bio Q3 2023 Earnings Report
Reported financial results for the third quarter ended September 30, 2023, and provided a business update.
Key Takeaways
Nuvation Bio reported a net loss of $19.6 million, or $(0.09) per share, and had cash, cash equivalents and marketable securities of $619.3 million as of September 30, 2023.
Phase 1 monotherapy study of NUV-868 and Phase 1b study of NUV-868 in combination with olaparib or enzalutamide are ongoing.
Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023.
Cash, cash equivalents, and marketable securities of $619.3 million as of September 30, 2023.
Reported a net loss of $19.6 million, or $(0.09) per share.
Nuvation Bio
Nuvation Bio
Forward Guidance
Nuvation Bio expects to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023.